Blood Cancer May Soon Be Curable With A Daily Pill

Blood cancer, which has traditionally given sufferers a survival time of just a few years, may soon be curable with the aid of a daily pill, say specialists.

Cancer specialists meeting in Melbourne this weekend are likely to discuss how in future doctors should treat myeloma, an incurable blood cancer which effects thousands of people.

Newly Identified Gene Variant Doubles Risk Of Blood Cancer
Scientists in California and Arizona have identified a gene variant that that they say nearly doubles the risk of a common type of blood cancer.

This form of cancer develops in the bone marrow, inhibits the production of normal blood cells, and causes symptoms such as anemia, fatigue and infections.

"We are seeing a major advance in the treatment of multiple myeloma," news.com.au quoted Royal Melbourne Hospital oncologist Professor Jeffrey Szer as saying in a statement.

"In the past five years for instance, myeloma patient survival, which has traditionally been three to four years, has been significantly extended with the availability of innovative new medicines," Szer added.

Potential Blood Cancer Therapy With an Arsenic-Based Agent
A team of experts led by researchers at Beth Israel Deaconess Medical Center (BIDMC) have found that an arsenic-based agent used in traditional Chinese medicine may help eliminate

Those present at the meeting are likely to hear that a medicine called Revlimid may possibly be used as an oral treatment for the condition.

"We are seeing a significant improvement in quality of life and cancer survival rates," Szer said.

Novel Targeted Therapy Shows Promise To Eliminate Leukemia Stem Cells
A piece of research has shown that it is possible to eliminate stem cells related to human acute myeloid leukemia (AML), a notoriously treatment-resistant blood cancer, using a new targeted therapy.

"There are a number of new treatment strategies that clinicians are adopting to enable them to achieve these outcomes.

"Revlimid is an example of an innovative new medicine that has a unique mechanism of action to kill cancer cells and prolong the patient's life. Compelling Revlimid clinical trail data is being discussed at (the) medical symposium this weekend with local and international experts, coinciding with the Leukaemia Foundation's public lecture," Szer added.

Source-ANI
ARU